{
    "clinical_study": {
        "@rank": "164689", 
        "arm_group": [
            {
                "arm_group_label": "Arm 1", 
                "arm_group_type": "Experimental", 
                "description": "First application:  Synera patch; Second application:  Placebo patch"
            }, 
            {
                "arm_group_label": "Arm 2", 
                "arm_group_type": "Experimental", 
                "description": "First application: Placebo patch; Second application: Synera patch"
            }
        ], 
        "brief_summary": {
            "textblock": "Synera, which is a heated topical patch containing both lidocaine and tetracaine, is\n      intended to reduce the pain associated with venipuncture and superficial dermatologic\n      procedures by numbing the skin. This study will test the effectiveness of the Synera\n      lidocaine/tetracaine patch when administered for 30 \u00b1 5 minutes to provide dermal anesthesia\n      in adult oncology patients undergoing venipuncture as part of their care, for treatment or\n      diagnostics (laboratory or imaging).  Compared to the use of the placebo patch, this study\n      hypothesizes that the difference of 1 cm on the 0-10 visual analogue scale (VAS) will be\n      observed 30 minutes after the use of the Synera patch. Pain intensity will be assessed by a\n      0-10 VAS"
        }, 
        "brief_title": "Synera Venipuncture Pain", 
        "completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Pain", 
            "Phlebotomy", 
            "Palliative Care"
        ], 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with any tumor type where treatment is received through venipuncture or any\n             procedure that is needle based or who require regular pharmacokinetic (PK) study.\n\n          -  Is 18 years of age or older.\n\n          -  Patients expected to undergo the first venipuncture procedure within 5 working days\n             of enrollment.\n\n          -  Male or female patients\n\n          -  Has signed the most recent Patient Informed Consent Form\n\n          -  Has signed a Patient Authorization Form (HIPPA)\n\n        Exclusion Criteria:\n\n          -  Patients with sensitivity to lidocaine, tetracaine, or any other component of the\n             product\n\n          -  Known sensitivity to any components of test materials (sulphites and adhesives)\n\n          -  Patients with damaged or broken skin at the designated patch site\n\n          -  Pregnant or breastfeeding women patients\n\n          -  Use of any immediate-release single-agent opioid product (ie, morphine, oxycodone,\n             hydrocodone, hydromorphone, oxymorphone, or tramadol) or combination products\n             containing acetaminophen or ibuprofen with one of these agents within 4 hours of the\n             patient's visit\n\n          -  Previous irradiation to the site of the patch"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 4, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01744197", 
            "org_study_id": "12112"
        }, 
        "intervention": {
            "arm_group_label": [
                "Arm 1", 
                "Arm 2"
            ], 
            "description": "All subjects will receive 2 patch applications during this study:  one Synera, one placebo. The 2 patch applications must be done on separate days.  Only 1 patch will be used per application.  Arm 1 subjects will receive Synera patch for the 1st application, and placebo for the second.  Arm 2 patients will receive placebo patch for the 1st application, and Synera patch for the second.", 
            "intervention_name": "Synera (lidocaine 70mg/tetracaine 70mg)", 
            "intervention_type": "Device", 
            "other_name": "Synera"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Tetracaine", 
                "Lidocaine"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Pain control", 
            "Needle stick pain", 
            "Venipuncture pain"
        ], 
        "lastchanged_date": "May 19, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Dallas", 
                    "country": "United States", 
                    "state": "Texas"
                }, 
                "name": "19 Locations Including"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effect of Synera in Reducing Pain Associated With Venipuncture and Superficial Dermatologic Procedures", 
        "overall_official": [
            {
                "affiliation": "US Oncology Research, McKesson Specialty Health", 
                "last_name": "Melanie Matson, RN, BSN", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "US Oncology Research, McKesson Specialty Health", 
                "last_name": "Laura T. Guerra, RN", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "February 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The primary efficacy endpoint is the subject's report of pain intensity regarding the venipuncture using a 0-10 VAS. The efficacy endpoints include the degree of pain reduction due to the needle stick experienced following the most recent administration of an analgesic drug, and how satisfied subjects are overall with the treatment provided to reduce pain by using the Global Assessment of Satisfaction with Venipuncture.", 
            "measure": "The degree of pain experienced during venipuncture after being treated with the Synera patch vs with placebo patch.", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01744197"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "results_reference": [
            {
                "PMID": "20975464", 
                "citation": "Wallace MS, Kopecky EA, Ma T, Brophy F, Campbell JC. Evaluation of the depth and duration of anesthesia from heated lidocaine/tetracaine (Synera) patches compared with placebo patches applied to healthy adult volunteers. Reg Anesth Pain Med. 2010 Nov-Dec;35(6):507-13."
            }, 
            {
                "PMID": "19151049", 
                "citation": "Sawyer J, Febbraro S, Masud S, Ashburn MA, Campbell JC. Heated lidocaine/tetracaine patch (Synera, Rapydan) compared with lidocaine/prilocaine cream (EMLA) for topical anaesthesia before vascular access. Br J Anaesth. 2009 Feb;102(2):210-5."
            }
        ], 
        "secondary_outcome": {
            "measure": "Adverse events associated with the Synera patch vs placebo patch, primarily the degree of dermal irritation at each patch application site.", 
            "safety_issue": "Yes", 
            "time_frame": "6 months"
        }, 
        "source": "US Oncology Research", 
        "sponsors": {
            "collaborator": {
                "agency": "Nuvo Research Inc.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "US Oncology Research", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}